Pictet Asset Management
SUPN icon

Pictet Asset Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Pictet Asset Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.2M Sell
432,478
-18,286
-4% -$878K 0.02% 530
2026
Q1 		$22.3M Sell
450,764
-32,635
-7% -$1.66M 0.02% 481
2025
Q4 		$24.8M Sell
483,399
-25,526
-5% -$1.24M 0.02% 478
2025
Q3 		$24.2M Sell
508,925
-45,557
-8% -$1.83M 0.02% 476
2025
Q2 		$17.3M Buy
554,482
+10,569
+2% +$339K 0.02% 544
2025
Q1 		$17.6M Buy
543,913
+17,661
+3% +$626K 0.02% 528
2024
Q4 		$19M Sell
526,252
-34,343
-6% -$1.21M 0.02% 515
2024
Q3 		$17.2M Buy
560,595
+14,696
+3% +$459K 0.02% 531
2024
Q2 		$14.6M Sell
545,899
-444,137
-45% -$12.9M 0.02% 549
2024
Q1 		$33.6M Sell
990,036
-56,046
-5% -$1.67M 0.04% 380
2023
Q4 		$30.3M Buy
1,046,082
+125,530
+14% +$3.33M 0.03% 388
2023
Q3 		$25.4M Buy
+920,552
New +$28M 0.03% 404

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Pictet Asset Management's SUPN Position: Q2 2026 in Review

Pictet Asset Management reduced its Supernus Pharmaceuticals (SUPN) stake by 4.1% in Q2 2026, selling an estimated $878K and leaving 432,478 shares worth $20.2M. The position accounts for 0.02% of the portfolio, ranked #530.

Pictet Asset Management first reported a position in SUPN in Q3 2023 and has held it in 12 quarters since. The position peaked at $33.6M in Q1 2024. 335 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • Pictet Asset Management held 432,478 shares of Supernus Pharmaceuticals worth $20.2M as of Q2 2026.
  • Pictet Asset Management sold 18,286 Supernus Pharmaceuticals shares in Q2 2026, an estimated $878K.
  • Supernus Pharmaceuticals made up 0.02% of Pictet Asset Management's portfolio in Q2 2026, its #530 holding.
  • Pictet Asset Management first reported a position in Supernus Pharmaceuticals in Q3 2023 and has held it in 12 quarters since.
  • Pictet Asset Management's Supernus Pharmaceuticals position peaked at $33.6M in Q1 2024.
  • 335 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Pictet Asset Management's 13F filing for Q2 2026, filed 30 Jul 2026.